James Healy

Managing Partner

2000 - Current

James Healy, M.D., PhD. Medical scientist, proven investor and value-added board member with 20+ years’ experience funding tomorrow’s cures. Dr. Healy finances companies in the US and Europe that are developing innovative therapies that can be transformative for patients. At Sofinnova he has funded twelve products that were approved by the FDA or EMA. Twenty-one of his investments have gone public and eleven have been acquired as private or public companies. Jim received a B.A. in Molecular Biology and B.A. Scandinavian Studies from UC Berkeley where he graduated with Honors and received the Departmental Citation. He subsequently completed the Medical Scientist Training Program and received his MD and PhD in Immunology from Stanford University where he was a Beckman Scholar and received the Novartis Foundation Bursary Award. He authored or co-authored thirteen scientific articles and reviews, including three papers published in Nature. He has lectured on entrepreneurship at Stanford University and served on the boards of the Executive Committee at UC Berkeley, the Biotechnology Industry Organization (BIO) and the National Venture Capital Association (NVCA). Previous investments include Amarin (AMRN), Appelis (APLS), Audentes (BOLD), Cellective, Cotherix (CTRX), Durata (DRTX), Hyperion (HYPN), InterMune (ITMN), Movetis (MOVE), Nextwave, Novacea (NOVA), Preglem, Prestwick, Salveo and Tesaro (TSRO). He currently sits on the board of directors of Ascendis (ASND), Coherus (CHRS), Iterum (ITRM), Natera (NTRA), Nucana (NCNA), Obseva (OBSV) and Y-Mabs (YMAB).

Chairman Of The Board

2019

Board Member, Lead Independent Director

2021

Board Member

2019

Board Observer

2018

Board Member

2014

Board Member

2014

Board Member

2014

Board Member

2017

Board Member

2014

Lead Investor